Georgia Mountain News

WASHINGTON, D.C. – Rep. Earl L. “Buddy” Carter (R-GA) has criticized President Biden's Inflation 'Reduction' Act, particularly focusing on the government-controlled drug pricing mandates. Carter expressed his concerns about the impact of these mandates on medical innovation and patient access to treatments.

In a statement, Carter condemned the legislation, stating, "The drug pricing mandates in President Biden’s so-called Inflation ‘Reduction’ Act are some of the worst pieces of legislation I’ve seen during my time in Congress." He further added, "American innovation cures the world. Instead of incentivizing more research and development, this administration is choosing to push unworkable price controls that have already resulted in patients losing access to several cancer drugs."

Expressing worry about the potential consequences, Carter questioned, "What other cures and treatments will be excluded from patients because of this? The cure for cancer, diabetes, Alzheimer’s? Patients can’t afford to find out."

Drawing from his experience as a pharmacist, Carter emphasized the importance of ensuring affordable and high-quality healthcare for all Americans. He suggested addressing lower prescription drug costs without compromising research and development by focusing on reining in pharmacy benefit managers (PBMs).

Carter concluded by affirming his commitment to working with House Republicans to prioritize patient well-being in healthcare policies. He extended an invitation to the Administration to collaborate on creating a healthcare system that prioritizes patients over profits.